Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital
Punzalan et al.,
Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients..,
Frontiers in Immunology, doi:10.3389/fimmu.2023.1123497
Prospective study of 400 hospitalized patients in the Philippines, showing higher progression with remdesivir in unadjusted results, without statistical significance.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 42.0% higher, RR 1.42, p = 0.12, treatment 47 of 224 (21.0%), control 26 of 176 (14.8%).
|
risk of progression, 58.9% higher, RR 1.59, p = 0.001, treatment 93 of 224 (41.5%), control 46 of 176 (26.1%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Punzalan et al., 28 Feb 2023, prospective, Philippines, peer-reviewed, mean age 56.0, 17 authors, study period October 2020 - September 2021.
Contact:
jimbz11@gmail.com.
Abstract: TYPE Original Research
PUBLISHED 28 February 2023
DOI 10.3389/fimmu.2023.1123497
OPEN ACCESS
EDITED BY
Pietro Ghezzi,
University of Urbino Carlo Bo, Italy
REVIEWED BY
Andreu Comas-Garcia,
Autonomous University of San Luis Potosı´,
Mexico
Andrew Weber,
Northwell Health, United States
Antonio Lalueza,
University Hospital October 12, Spain
*CORRESPONDENCE
Jaime Alfonso M. Aherrera
jimbz11@gmail.com
SPECIALTY SECTION
This article was submitted to
Inflammation,
a section of the journal
Frontiers in Immunology
RECEIVED 14 December 2022
ACCEPTED 14 February 2023
PUBLISHED 28 February 2023
CITATION
Punzalan FER, Aherrera JAM,
de Paz-Silava SLM, Mondragon AV,
Malundo AFG, Tan JJE, Tantengco OAG,
Quebral EPB, Uy MNAR, Lintao RCV,
Dela Rosa JGL, Mercado MEP, Avenilla KC,
Poblete JB, Albay AB Jr, David-Wang AS
and Alejandria MM (2023) Utility of
laboratory and immune biomarkers in
predicting disease progression and
mortality among patients with moderate to
severe COVID-19 disease at a Philippine
tertiary hospital.
Front. Immunol. 14:1123497.
doi: 10.3389/fimmu.2023.1123497
COPYRIGHT
© 2023 Punzalan, Aherrera, de Paz-Silava,
Mondragon, Malundo, Tan, Tantengco,
Quebral, Uy, Lintao, Dela Rosa, Mercado,
Avenilla, Poblete, Albay, David-Wang and
Alejandria. This is an open-access article
distributed under the terms of the Creative
Commons Attribution License (CC BY). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.
Utility of laboratory and immune
biomarkers in predicting disease
progression and mortality among
patients with moderate to severe
COVID-19 disease at a Philippine
tertiary hospital
Felix Eduardo R. Punzalan 1,2, Jaime Alfonso M. Aherrera 1,2*,
Sheriah Laine M. de Paz-Silava 3, Alric V. Mondragon 1,2,
Anna Flor G. Malundo 1,2, Joanne Jennifer E. Tan 1,2,
Ourlad Alzeus G. Tantengco 4,5, Elgin Paul B. Quebral 2,
Mary Nadine Alessandra R. Uy 1,2, Ryan C. V. Lintao 2,
Jared Gabriel L. Dela Rosa 2, Maria Elizabeth P. Mercado 6,
Krisha Camille Avenilla 2, Jonnel B. Poblete 1,
Albert B. AlbayJr.1,2, Aileen S. David-Wang 1,2
and Marissa M. Alejandria 1,2,7
1
Department of Medicine, Philippine General Hospital, University of the Philippines Manila,
Manila, Philippines, 2 College of Medicine, University of the Philippines Manila, Manila, Philippines,
3
College of Public Health, University of the Philippines Manila, Manila, Philippines, 4 Department of
Physiology, College of Medicine, University of the Philippines Manila, Manila, Philippines,
5
Department of Biology, College of Science, De La Salle University, Manila, Philippines,
6
Department of Clinical Epidemiology, Faculty of Medicine and Surgery, University of Santo Tomas,
Manila, Philippines, 7 Institute of Clinical Epidemiology, National Institutes of Health, University of the
Philippines Manila, Manila, Philippines
Purpose: This study was performed to determine the clinical biomarkers and
cytokines that may be associated with disease progression and in-hospital
mortality in a cohort of hospitalized patients with RT-PCR confirmed moderate
to severe COVID-19 infection from October 2020 to September 2021, during the
first wave of COVID-19 pandemic before the advent of vaccination.
Patients and methods: Clinical..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit